Henry Mankin

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Diagnosis, classification, and management of soft tissue sarcomas
    Henry J Mankin
    Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Control 12:5-21. 2005
  2. ncbi request reprint Internal hemipelvectomy for the management of pelvic sarcomas
    Henry J Mankin
    Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, Gray 6 Orthopaedics, Boston, 02114, USA
    Surg Oncol Clin N Am 14:381-96. 2005
  3. ncbi request reprint Total femur replacement procedures in tumor treatment
    Henry J Mankin
    Orthopaedic Oncology Service, Massachusetts General Hospital and the Harvard Medical School, Boston, MA 02114, USA
    Clin Orthop Relat Res 438:60-4. 2005
  4. ncbi request reprint Treatment of proximal humeral chondrosarcoma with resection and allograft
    Anastasios Mourikis
    Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    J Shoulder Elbow Surg 16:519-24. 2007
  5. doi request reprint Pleomorphic spindle cell sarcoma (PSCS) formerly known as malignant fibrous histiocytoma (MFH): a complex malignant soft-tissue tumor
    H J Mankin
    Department of Orthopaedic Oncology, Massachusetts General Hospital, Boston, MA, USA
    Musculoskelet Surg 96:171-7. 2012
  6. pmc Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
    Keinosuke Ryu
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 10:187. 2010
  7. ncbi request reprint Erlenmeyer flasking of a child's bones: a diagnostic puzzle
    Henry J Mankin
    Orthopaedic Oncology Service and Developmental Neurogenetics Clinic, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Am J Orthop (Belle Mead NJ) 34:393-5. 2005
  8. ncbi request reprint Paget's sarcoma: a historical and outcome review
    Henry J Mankin
    Orthopaedic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Orthop Relat Res 438:97-102. 2005
  9. ncbi request reprint A questionnaire study for 128 patients with Gaucher disease
    H J Mankin
    The Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Genet 69:209-17. 2006
  10. ncbi request reprint Aneurysmal bone cyst: a review of 150 patients
    Henry J Mankin
    Orthopedic Oncology Service, Orthopedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 23:6756-62. 2005

Research Grants

Collaborators

Detail Information

Publications81

  1. ncbi request reprint Diagnosis, classification, and management of soft tissue sarcomas
    Henry J Mankin
    Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Control 12:5-21. 2005
    ..Advances in imaging, as well as improvements in surgical techniques and adjunctive treatment methods, have improved care for patients with these unusual disorders...
  2. ncbi request reprint Internal hemipelvectomy for the management of pelvic sarcomas
    Henry J Mankin
    Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, Gray 6 Orthopaedics, Boston, 02114, USA
    Surg Oncol Clin N Am 14:381-96. 2005
  3. ncbi request reprint Total femur replacement procedures in tumor treatment
    Henry J Mankin
    Orthopaedic Oncology Service, Massachusetts General Hospital and the Harvard Medical School, Boston, MA 02114, USA
    Clin Orthop Relat Res 438:60-4. 2005
    ..None of the patients required an amputation. The procedure is complex and metallic implant and allograft implantation require wide surgery and special systems of reconstruction...
  4. ncbi request reprint Treatment of proximal humeral chondrosarcoma with resection and allograft
    Anastasios Mourikis
    Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    J Shoulder Elbow Surg 16:519-24. 2007
    ....
  5. doi request reprint Pleomorphic spindle cell sarcoma (PSCS) formerly known as malignant fibrous histiocytoma (MFH): a complex malignant soft-tissue tumor
    H J Mankin
    Department of Orthopaedic Oncology, Massachusetts General Hospital, Boston, MA, USA
    Musculoskelet Surg 96:171-7. 2012
    ....
  6. pmc Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
    Keinosuke Ryu
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 10:187. 2010
    ....
  7. ncbi request reprint Erlenmeyer flasking of a child's bones: a diagnostic puzzle
    Henry J Mankin
    Orthopaedic Oncology Service and Developmental Neurogenetics Clinic, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Am J Orthop (Belle Mead NJ) 34:393-5. 2005
  8. ncbi request reprint Paget's sarcoma: a historical and outcome review
    Henry J Mankin
    Orthopaedic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Orthop Relat Res 438:97-102. 2005
    ....
  9. ncbi request reprint A questionnaire study for 128 patients with Gaucher disease
    H J Mankin
    The Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Genet 69:209-17. 2006
    ..The results show that many of the patients still have fairly extensive problems, which could possibly be helped by some alterations in treatment protocols...
  10. ncbi request reprint Aneurysmal bone cyst: a review of 150 patients
    Henry J Mankin
    Orthopedic Oncology Service, Orthopedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 23:6756-62. 2005
    ..We have reviewed a series of 150 aneurysmal bone cysts treated over the last 20 years...
  11. doi request reprint Pigmented villonodular synovitis of joints
    Henry Mankin
    Department of Orthopaedics, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Surg Oncol 103:386-9. 2011
    ..The 215 cases from our hospital are current (1972-2009) and those 62 from the Jaffe collection from 1920 to 1968...
  12. doi request reprint Non-ossifying fibroma, fibrous cortical defect and Jaffe-Campanacci syndrome: a biologic and clinical review
    Henry J Mankin
    Orthopaedic Research Laboratories, Massachusetts General Hospital, Boston, MA 02114, USA
    Chir Organi Mov 93:1-7. 2009
    ..In addition, these patients have some systemic and dermal findings resembling those seen in patients with Type 1 neurofibromatosis...
  13. ncbi request reprint A happy outcome to a bad problem
    Henry J Mankin
    Orthopaedic Oncology and Reproductive Endocrinology Services, Massachusetts General Hospital, Boston, MA 02114, USA
    J Bone Joint Surg Am 84:1251-3. 2002
  14. ncbi request reprint Treatment of giant cell tumors with allograft transplants: a 30-year study
    Henry J Mankin
    Orthopaedic Oncology Service, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Orthop Relat Res 439:144-50. 2005
    ....
  15. pmc Characterization and analysis of human chordoma cell lines
    Cao Yang
    Department of Orthopaedic Surgery, Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Spine (Phila Pa 1976) 35:1257-64. 2010
    ..An experimental study to investigate the characterization of 3 chordoma cell lines...
  16. pmc Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS ONE 5:e10764. 2010
    ..However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy...
  17. doi request reprint RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 64:607-14. 2009
    ..To identify the apoptosis genes involved in the multidrug resistant phenotype of osteosarcoma...
  18. pmc The kinase Mirk is a potential therapeutic target in osteosarcoma
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Carcinogenesis 31:552-8. 2010
    ..This highlights Mirk's potential to serve as a promising target for molecular therapy in the treatment of osteosarcoma...
  19. doi request reprint Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 67:439-46. 2011
    ..To better understand the mechanisms of cytotoxicity and cell death induced by HDACI PCI-24781 in bone sarcoma cells...
  20. doi request reprint Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Apoptosis 14:124-33. 2009
    ..These results suggest that GADD45alpha may play a role in drug-induced apoptosis, as well as multidrug resistance in osteosarcoma cells...
  21. doi request reprint Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Lett 293:220-9. 2010
    ..The development of more potent inhibitors that target PLK1 may open doors to a new range of anti-cancer strategies in osteosarcoma...
  22. doi request reprint Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo
    Xianzhe Liu
    Department of Orthopaedic Surgery, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Anticancer Drugs 22:444-53. 2011
    ..Finally, in mouse osteosarcoma xenografts, BI 2536-treated mice had significantly smaller tumors compared with the control mice. These findings offer evidence of the potential role for targeting PLK1 in osteosarcoma therapy...
  23. doi request reprint Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Orthop Res 28:746-52. 2010
    ..Our results demonstrate that some miRNAs are differentially expressed in chordoma and, in particular, miRNA-1 may have a functional effect on chordoma tumor pathogenesis...
  24. doi request reprint ROCK1 as a potential therapeutic target in osteosarcoma
    Xianzhe Liu
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 29:1259-66. 2011
    ..These findings suggest that knockdown of ROCK1 inhibits proliferation and induces apoptosis in osteosarcoma cell lines. ROCK1 may be a promising therapeutic target for the treatment of osteosarcoma patients...
  25. doi request reprint Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking
    Michiro Susa
    Department of Orthopaedic Surgery, and SarcomaBiology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 9:3342-50. 2010
    ..In conclusion, our results suggest that osteosarcoma cell proliferation and survival are dependent on GAK. These findings may lead to the development of new therapeutic options for osteosarcoma...
  26. pmc MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 10:1337-45. 2011
    ..Restoring miR-199a-3p's function may provide therapeutic benefits in osteosarcoma...
  27. ncbi request reprint Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells
    Bin Jia
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Department of Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
    Cancer Lett 342:104-12. 2014
    ..These findings suggest that CDK11 is critical for the growth and proliferation of liposarcoma cells. CDK11 may be a promising therapeutic target for the treatment of liposarcoma patients. ..
  28. pmc Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 9:399. 2009
    ....
  29. pmc Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Jackson Building, Boston, Massachusetts 02114, USA
    Mol Cancer Ther 8:2122-30. 2009
    ..Our data suggest that inhibition of IGF-IR with PPP offers a novel and selective therapeutic strategy for ostosarcoma, and at the same time, PPP is effective at reversing the drug-resistant phenotype in osteosarcoma cell lines...
  30. ncbi request reprint Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis
    Keinosuke Ryu
    Department of Orthopedic Surgery, Massachusetts General Hospital, Center for Sarcoma and Connective Tissue Oncology, 55 Fruit St Jackson 1115, Boston, Massachusetts 02114, USA
    J Orthop Res 28:971-8. 2010
    ..Our results suggest that Stat3 may be a prognostic indicator and potential therapeutic target for osteosarcoma. Blocking the pathway of Stat3 may lead to develop new therapeutic strategies against osteosarcoma...
  31. doi request reprint Targeting hedgehog-GLI-2 pathway in osteosarcoma
    Wen Yang
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 31:502-9. 2013
    ..These findings suggest GLI-2 is required for osteosarcoma cell proliferation and survival. GLI-2 may be exploited as a therapeutic target for the treatment of osteosarcoma patients...
  32. pmc CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 63:681-9. 2009
    ..Inhibition is likely achieved through multiple points within these pathways. In a model system of established acquired drug resistance, CCDO-Me is effective at partially reversing the drug-resistance phenotype...
  33. doi request reprint A novel target for treatment of chordoma: signal transducers and activators of transcription 3
    Cao Yang
    Department of Orthopaedic Surgery, Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Mol Cancer Ther 8:2597-605. 2009
    ..In conclusion, the Stat3 pathway is constitutively activated in chordomas and the level of expression may serve as a predictor for prognosis. Blockade of the Stat3 pathway represents a potential strategy for future treatment...
  34. doi request reprint Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay
    Michiro Susa
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Biomol Screen 15:287-96. 2010
    ..The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients...
  35. ncbi request reprint Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology and Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 18:4580-8. 2012
    ..Identification of new targeted therapies is critical to improving the survival rate of patients with osteosarcoma. The goal of this study is to identify kinase based potential therapeutic target in osteosarcomas...
  36. doi request reprint Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Med Chem 55:3113-21. 2012
    ..In conclusion, 11 and derivatives of this compound may hold therapeutic value in the treatment of MDR-dependent cancers...
  37. doi request reprint Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma
    Cao Yang
    Department of Orthopaedic Surgery, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Spine (Phila Pa 1976) 35:1668-75. 2010
    ..An experimental study to investigate the activation of Src/Stat3 pathways in chordomas and blockage of this pathway as a potential strategy for chordoma treatment...
  38. doi request reprint Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer
    Yuqi Guo
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 16:5759-69. 2010
    ..We then looked for enhancing paclitaxel sensitivity in multidrug-resistant ovarian cancer cell lines...
  39. ncbi request reprint Alveolar soft part sarcoma: a rare and enigmatic entity
    Megan E Anderson
    Harvard Combined Orthopaedic Oncology Program, Boston, MA 02215, USA
    Clin Orthop Relat Res 438:144-8. 2005
    ..Current treatment results in good local control of primary tumors, but poor control of metastatic tumors. New approaches to treatment of metastatic alveolar soft part sarcoma must be investigated and applied...
  40. pmc Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, 02114
    J Orthop Res 32:695-701. 2014
    ..These results indicate that suppressed miR-1 expression in chordoma may in part be a driver for tumor growth, and that miR-1 has potential to serve as prognostic biomarker and therapeutic target for chordoma patients...
  41. pmc Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
    Shang Guo
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America Shanghai Sixth People s Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
    PLoS ONE 9:e93996. 2014
    ..Targeting the PI3K/AKT/pathway with small molecule inhibitors in combination with chemotherapy could be exploited as a novel strategy in the treatment of liposarcoma. ..
  42. pmc Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma
    Linlin Zhang
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China
    PLoS ONE 8:e75851. 2013
    ..By Kaplan-Meier analysis, brachyury expression failed to produce any significant relationship with the overall survival rate. In conclusion, brachyury expression is not a prognostic indicator in chordoma. ..
  43. ncbi request reprint Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma
    Joseph Schwab
    Department of Orthopedic Surgery, Section of Orthopedic Oncology, Sarcoma Research Laboratory, Massachusetts General Hospital, Boston, MA 02114, U S A
    Anticancer Res 29:1867-71. 2009
    ..PI-103 is a inhibitor of PI3K/AKT and mTOR activation. This study aims to determine whether the PI3K/mTOR pathway was active in chordomas and whether their inhibition could lead to decreased proliferation and increased apoptosis...
  44. ncbi request reprint Chondromyxoid fibroma: a rarely encountered and puzzling tumor
    Ana Lersundi
    Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Orthop Relat Res 439:171-5. 2005
    ..Tumors treated by excision did not recur. The most difficult problem with chondromyxoid fibroma is pathologic identity because it often is confused with more aggressive tumors that may metastasize...
  45. ncbi request reprint Distal lower extremity sarcomas: frequency of occurrence and patient survival rate
    Trisha Zeytoonjian
    Orthopaedic Oncology Service, Massachusetts General Hospital, Boston 02114, USA
    Foot Ankle Int 25:325-30. 2004
    ..Primary sarcomas in the distal leg, tibia, fibula, ankle, and foot are uncommon and are believed to be less malignant than those that arise in other sites, but only limited information is available to support this contention...
  46. ncbi request reprint Treatment and outcome of 82 patients with angiosarcoma
    John A Abraham
    Orthopedic Oncology, Department of Orthopedics, Massachusetts General Hospital, Yawkey 7B 7926, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Ann Surg Oncol 14:1953-67. 2007
    ..Angiosarcomas are an uncommon type of malignancy that are generally thought to behave usually in a locally aggressive fashion; they often metastasize to distant sites...
  47. ncbi request reprint Imaging of pseudoneoplastic masses associated with allografts
    Taj M Kattapuram
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Yawkey 6036, 55 Fruit Street, Boston, MA 02114, USA
    Skeletal Radiol 36:747-53. 2007
    ..The objective of this study is to describe the imaging features of non-neoplastic masses suspected of being tumor recurrences adjacent to allografts. The allografts were utilized for the treatment of various musculoskeletal tumors...
  48. ncbi request reprint Osteoblastoma: a 30-year study of 99 cases
    Micah Berry
    Harvard Medical School, Boston, Massachusetts, USA
    J Surg Oncol 98:179-83. 2008
    ..In the current study we characterize osteoblastoma by its demographic and anatomic prevalence. We looked at rates of recurrence as related to treatment...
  49. ncbi request reprint Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor
    Lily Park
    Department of Radiation, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 65:1514-21. 2006
    ..To assess the efficacy of definitive treatment of sacral chordoma by high-dose proton/photon-beam radiation therapy alone or combined with surgery...
  50. pmc ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e6967. 2009
    ..ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug resistance, but the mechanisms which lead to resistance are not yet understood...
  51. ncbi request reprint Advantage of limb salvage over amputation for proximal lower extremity tumors
    Poonam K Pardasaney
    MGH Institute of Health Professions, Boston, Massachusetts 02129, USA
    Clin Orthop Relat Res 444:201-8. 2006
    ..Limb salvage offers a functional advantage at proximal tumor locations. Level of Evidence: Therapeutic study, Level III (retrospective, comparative study). See the Guidelines for Authors for a complete description of levels of evidence...
  52. ncbi request reprint Clear cell sarcoma of soft tissues
    Sara Sofia Malchau
    Orthopaedic Oncology Service, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Surg Oncol 95:519-22. 2007
    ..The purpose of this article is to warn the readers of the dangers related to treating this seemingly benign lesion and urge them to perform wide surgery and utilize adjuvant therapy...
  53. doi request reprint Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom St Jackson 1106, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 63:1121-9. 2009
    ..The present study was performed to elucidate the relationship between the expression of ABCB1/MDR1 and ABCC1/MRP1 with resistance to either ET-743 or PM00104...
  54. ncbi request reprint Radiation therapy for control of soft-tissue sarcomas resected with positive margins
    Thomas F DeLaney
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 67:1460-9. 2007
    ..Positive margins (PM) remain after surgery in some soft-tissue sarcoma (STS) patients. We investigated the efficacy of radiation therapy (RT) in STS patients with PM...
  55. ncbi request reprint Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas
    Thomas F DeLaney
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 56:1117-27. 2003
    ..We report the mature outcome data on 48 treated patients and compare them with the data of an historical matched control patient population...
  56. ncbi request reprint Multiple myeloma with a pathologic fracture during pregnancy. A case report
    Christopher L Forthman
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Bone Joint Surg Am 86:1284-8. 2004
  57. ncbi request reprint Osteoid osteoma: percutaneous treatment with radiofrequency energy
    Daniel I Rosenthal
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 199 Cambridge Street, Boston, MA 02114, USA
    Radiology 229:171-5. 2003
    ..To report our experience with technical success, complications, and long-term clinical success of radiofrequency (RF) ablation of osteoid osteoma...
  58. ncbi request reprint Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions
    Anwar Hau
    Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Skeletal Radiol 31:349-53. 2002
    ..The lowest success rates occurred in 26 patients with infectious diseases (50%). We conclude that these procedures remain the logical and safe choice for diagnostic studies of patients with lesions of the musculoskeletal system...
  59. ncbi request reprint Malignant transformation of synovial chondromatosis of the shoulder to chondrosarcoma. A case report
    Alexander P Sah
    Department of Orthopaedic Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    J Bone Joint Surg Am 89:1321-8. 2007
  60. ncbi request reprint Locking versus standard plates for allograft fixation after tumor resection in children and adolescents
    Peter J Buecker
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Pediatr Orthop 26:680-5. 2006
    ..This investigation was undertaken to assess the performance of locking plates in comparison to standard compression plates for allograft fixation after resection of malignant primary skeletal tumors...
  61. doi request reprint Adamantinoma: an unusual bone tumour
    Pedro Roque
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Chir Organi Mov 92:149-54. 2008
    ..Only three of the patients died of disease with the time until death ranging from 10 to 17 years. Recurrence occurred in only three patients and the allograft success rate in terms of function was 71% at a mean time of 10 years...
  62. ncbi request reprint The changes in major limb reconstruction as a result of the development of allografts
    Henry J Mankin
    Ortopaedic Sevice, Massachussetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Chir Organi Mov 88:101-13. 2003
    ..Secondary infection following operative procedures to repair fracture or graft non-union occurred in 53 cases and reduced the success rate to less then 30%. No patients died of infection...
  63. ncbi request reprint Langerhans cell histiocytosis
    Kevin Bradford Hoover
    Musculoskeletal Radiology, Massachusetts General Hospital, Yawkey 6E 55 Fruit Street, Boston, MA 02114, USA
    Skeletal Radiol 36:95-104. 2007
    ..It focuses on the radiographic findings and imaging modalities that are the most useful in disease diagnosis and management...
  64. ncbi request reprint Giant-cell tumor of the distal forearm
    Neil G Harness
    Orthopaedic Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Hand Surg Am 29:188-93. 2004
    ..We have studied the results from our institution for 49 patients with giant-cell tumors of the distal forearm treated from 2 to 28 years (mean, 14 +/- 7 years) and compared the results for different methods of treatment...
  65. ncbi request reprint Jaffe-Campanacci syndrome. A case report and review of the literature
    Mohammad Anwar Hau
    Orthopaedic Oncology Service and Department of Pathology, Maassachusetts General Hospital, Boston 02114, USA
    J Bone Joint Surg Am 84:634-8. 2002
  66. ncbi request reprint Soft tissue sarcoma resection volume associated with wound-healing complications
    David S Geller
    Orthopaedic Oncology Service, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Clin Orthop Relat Res 459:182-5. 2007
    ..Mean volume of resected tissue in the group of patients treated with primary flap coverage was 1908 cm3, over twice as large as the mean volume of resected tissue in the group of patients treated with primary closure...
  67. doi request reprint Extra-abdominal desmoid tumors: a report of 234 cases
    Henry J Mankin
    Orthopaedic Oncology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA hmankin partners org
    J Surg Oncol 102:380-4. 2010
    ..To report on the clinical presentation and outcome for 234 patients with extra-abdominal desmoids tumors...
  68. ncbi request reprint Improved survival for sarcomas of the wrist and hand
    Peter J Buecker
    Orthopaedic Oncology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Hand Surg Am 31:452-5. 2006
    ..To evaluate survival characteristics of malignant hand tumors compared with those occurring in other musculoskeletal locations over a 30-year period...
  69. pmc Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Mol Cancer Ther 7:2377-85. 2008
    ..Finally, overexpression of PRP-4 in drug-sensitive cells could induce a modest level of drug resistance to paclitaxel, doxorubicin, and vincristine...
  70. ncbi request reprint Lower-extremity lymphangiomatosis. A case report with a seventeen-year follow-up
    Karl Schultz
    Department of Orthopaedic Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    J Bone Joint Surg Am 87:162-7. 2005
  71. ncbi request reprint Cyclooxygenase-2 expression in chondrosarcoma
    Karen M Sutton
    Orthopedic Biological Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Oncology 66:275-80. 2004
    ..There is now a mounting body of information that strongly implies that COX-2 inhibitors may be of some value in the management of patients with carcinomas, and most recently several similar reports have appeared relating to sarcomas...
  72. ncbi request reprint Osteosarcoma of the spine: experience in 26 patients treated at the Massachusetts General Hospital
    Andrew J Schoenfeld
    Department of Orthopaedic Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Spine J 10:708-14. 2010
    ..Because of the low incidence, treatment recommendations for spinal osteosarcoma are guided by the results of small series and case reports. Many include patients who presented for treatment over the course of three to four decades...
  73. ncbi request reprint Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation
    Laurence de Leval
    Department of Pathology, Massachusetts General Hospital, Boston, 02114, USA
    Am J Surg Pathol 27:1269-77. 2003
    ..0046). In conclusion, a GC-like immunophenotype characterizes roughly half of large B-cell lymphomas of bone and is associated with an improved survival...
  74. ncbi request reprint Metabolic bone disease: a review and update
    Henry J Mankin
    Treadwell Library and Smith Peterson Library, Massachusetts General Hospital, Boston, Massachusetts, USA
    Instr Course Lect 57:575-93. 2008
    ..It is essential that orthopaedists recognize these conditions, provide a correct diagnosis, and use appropriate preventive and therapeutic treatments...
  75. ncbi request reprint Metabolic bone disease: an update
    Henry J Mankin
    Harvard Medical School, Orthopaedic Oncology Service, Massachusetts General Hospital, Boston, Massachusetts, USA
    Instr Course Lect 52:769-84. 2003
    ..Finally, the transfer of calcium across lumens such as the gut, kidney, or bone requires a system, which consists of parathyroid hormone and 1,25-dihydroxyvitamin D and a low phosphate level...
  76. ncbi request reprint Clinical outcome in chordoma: utility of flow cytometry in DNA determination
    Sigurd Berven
    Department of Orthopaedic Surgery, Mount Sinai Medical Center, San Francisco, USA
    Spine (Phila Pa 1976) 27:374-9. 2002
    ..A retrospective review of 100 patients with chordoma of the lumbar spine and sacrum. Twenty-three patients had flow cytometry data available and a minimum follow-up period of 5 years...
  77. pmc Osteoarticular and total elbow allograft reconstruction with severe bone loss
    F Daniel Kharrazi
    Kerlan Jobe Orthopaedic Clinic, 6801 Park Terrace Dr, Los Angeles, CA 90045, USA
    Clin Orthop Relat Res 466:205-9. 2008
    ..Complications occurred in six of 19 patients. Hemiarticular elbow allograft reconstruction is useful for limb salvage with massive bone loss. Total elbow allograft reconstructions have a high failure rate in the mid-term...
  78. ncbi request reprint THE CLASSIC: The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. The Journal of Bone and Joint Surgery, 1982;64:1121-1127
    Henry J Mankin
    Clin Orthop Relat Res 450:4-10. 2006
  79. ncbi request reprint Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. 1986
    Michael A Simon
    J Bone Joint Surg Am 87:2822. 2005
  80. ncbi request reprint Knee mass from severe metallosis after failure of a metal-backed patellar component total knee arthroplasty
    F Daniel Kharrazi
    Kerlan Jobe Orthopaedic Clinic, Los Angeles, California 90045, USA
    Am J Orthop (Belle Mead NJ) 37:E38-41. 2008
  81. ncbi request reprint Guidance on the use of miglustat for treating patients with type 1 Gaucher disease
    Neal J Weinreb
    University Research Foundation for Lysosomal Storage Diseases and Northwest Oncology Hematology Associates PA, Coral Springs, Florida
    Am J Hematol 80:223-9. 2005
    ....

Research Grants7

  1. METABOLISM IN NORMAL AND OSTEOARTHRITIC CARTILAGE
    Henry Mankin; Fiscal Year: 1999
    ..It is further speculated that the study of serine proteinases produced by OA cartilage may have strong implications for the management of this debilitating disease. ..
  2. METABOLISM IN NORMAL AND OSTEOARTHRITIC CARTILAGE
    Henry Mankin; Fiscal Year: 1991
    ..The receptors for this cytokine on normal and OA chondrocytes will be quantitated. Further definition of these cartilage metabolic pathways are of primary importance in our understanding of osteoarthritis...
  3. METABOLISM IN NORMAL AND OSTEOARTHRITIC CARTILAGE
    Henry Mankin; Fiscal Year: 2000
    ..It is further speculated that the study of serine proteinases produced by OA cartilage may have strong implications for the management of this debilitating disease. ..
  4. METABOLISM IN NORMAL AND OSTEOARTHRITIC CARTILAGE
    Henry Mankin; Fiscal Year: 2001
    ..It is further speculated that the study of serine proteinases produced by OA cartilage may have strong implications for the management of this debilitating disease. ..